Given that the United States proceeds with sweeping revisions to its immunization schedules, an unexpected name appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who first made her name by questioning Covid shots during the pandemic and has zeroed in on alleged fatalities following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).
Agency leaders were set to reveal major revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, according to reports – a major change that would place the US at odds with a large portion of the international standard with little proof for improved outcomes. The announcement has been delayed until the next year.
Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to run the office this calendar year.
Høeg's temporary position may indicate a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon reevaluating already-approved immunizations at the FDA.
Høeg has often pushed for ending some childhood vaccine recommendations in the US in order to be more like Denmark's approach, a country with universal health coverage and a population about the population of Wisconsin’s.
So far public appearances, she has continued to focus on vaccines – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.
Dr. Høeg has no apparent experience in drug development, regulation or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since earlier this year.
“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in industry regulation.”
Previous directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, said Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who headed CBER have had.”
The drug center has an vast workload at the FDA, Woodcock emphasized.
“Many people just pays attention on the novel medication approvals, but the off-patent medication office clears thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and all of those must be supervised,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”
Furthermore, a significant management component to the role, which supervises in excess of 5,000 personnel. “It’s a massive management job, if you execute it properly,” Woodcock said.
When asked about questions about Dr. Høeg's credentials and whether this appointment represents greater collaboration among FDA leaders on vaccines, a press secretary said that the “questions stem from incorrect assumptions”.
“Her experience is consistent with the responsibilities of her role,” the official explained, citing the period Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.
As acting director, Høeg inherits the commissioner’s controversial fast-track approval initiative, a disputed one-day medication authorization process that reportedly concerned her preceding directors. “How are these medications being selected for this fast-track system? Who takes the decisions?” Dr. Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”
In general, he said, “the FDA seems to be moving towards more relaxed regulations of pharmaceuticals, aside from vaccines.”
Concerning immunizations, Dr. Høeg has a clearer, if concerning, history, critics observe. She authored a study using non-validated crowd-sourced reports to determine the rate of myocarditis following Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.
Included in her “wish list” for the current government encompassed revising rules for new vaccines and halting “non-essential” immunizations, she stated after the election on a audio program. At the FDA, Høeg has allegedly proposed excluding teenage boys from receiving COVID-19 vaccinations.
“She is an thorough ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the data in a extremely misleading, untruthful way,” Howard said.
Dr. Høeg became part of fellow dissenters, {like|
A software engineer and tech writer passionate about open-source projects and AI advancements.
